TY - JOUR
T1 - Chikungunya virus vaccine
T2 - a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventions
AU - Shaikh, Mohd Sayeed
AU - Faiyazuddin, Md
AU - Khan, Mubasshera Sabir
AU - Pathan, Shahbaz K.
AU - Syed, Imran J.
AU - Gholap, Amol D.
AU - Akhtar, Mohammad Shabib
AU - Sah, Ranjit
AU - Mehta, Rachana
AU - Sah, Sanjit
AU - Bonilla-Aldana, D. Katterine
AU - Luna, Camila
AU - Rodriguez-Morales, Alfonso J.
N1 - Publisher Copyright:
Copyright © 2024 Shaikh, Faiyazuddin, Khan, Pathan, Syed, Gholap, Akhtar, Sah, Mehta, Sah, Bonilla-Aldana, Luna and Rodriguez-Morales.
PY - 2024
Y1 - 2024
N2 - Chikungunya virus (CHIKV), a single-stranded RNA virus transmitted by Aedes mosquitoes, poses a significant global health threat, with severe complications observed in vulnerable populations. The only licensed vaccine, IXCHIQ, approved by the US FDA, is insufficient to address the growing disease burden, particularly in endemic regions lacking herd immunity. Monoclonal antibodies (mAbs), explicitly targeting structural proteins E1/E2, demonstrate promise in passive transfer studies, with mouse and human-derived mAbs showing protective efficacy. This article explores various vaccine candidates, including live attenuated, killed, nucleic acid-based (DNA/RNA), virus-like particle, chimeric, subunit, and adenovirus vectored vaccines. RNA vaccines have emerged as promising candidates due to their rapid response capabilities and enhanced safety profile. This review underscores the importance of the E1 and E2 proteins as immunogens, emphasizing their antigenic potential. Several vaccine candidates, such as CHIKV/IRES, measles vector (MV-CHIK), synthetic DNA-encoded antibodies, and mRNA-lipid nanoparticle vaccines, demonstrate encouraging preclinical and clinical results. In addition to identifying potential molecular targets for antiviral therapy, the study looks into the roles played by Toll-like receptors, RIG-I, and NOD-like receptors in the immune response to CHIKV. It also offers insights into novel tactics and promising vaccine candidates. This article discusses potential antiviral targets, the significance of E1 and E2 proteins, monoclonal antibodies, and RNA vaccines as prospective Chikungunya virus vaccine candidates.
AB - Chikungunya virus (CHIKV), a single-stranded RNA virus transmitted by Aedes mosquitoes, poses a significant global health threat, with severe complications observed in vulnerable populations. The only licensed vaccine, IXCHIQ, approved by the US FDA, is insufficient to address the growing disease burden, particularly in endemic regions lacking herd immunity. Monoclonal antibodies (mAbs), explicitly targeting structural proteins E1/E2, demonstrate promise in passive transfer studies, with mouse and human-derived mAbs showing protective efficacy. This article explores various vaccine candidates, including live attenuated, killed, nucleic acid-based (DNA/RNA), virus-like particle, chimeric, subunit, and adenovirus vectored vaccines. RNA vaccines have emerged as promising candidates due to their rapid response capabilities and enhanced safety profile. This review underscores the importance of the E1 and E2 proteins as immunogens, emphasizing their antigenic potential. Several vaccine candidates, such as CHIKV/IRES, measles vector (MV-CHIK), synthetic DNA-encoded antibodies, and mRNA-lipid nanoparticle vaccines, demonstrate encouraging preclinical and clinical results. In addition to identifying potential molecular targets for antiviral therapy, the study looks into the roles played by Toll-like receptors, RIG-I, and NOD-like receptors in the immune response to CHIKV. It also offers insights into novel tactics and promising vaccine candidates. This article discusses potential antiviral targets, the significance of E1 and E2 proteins, monoclonal antibodies, and RNA vaccines as prospective Chikungunya virus vaccine candidates.
KW - RNA vaccines
KW - chikungunya
KW - epidemiology
KW - immunology
KW - prevention
KW - vaccines
UR - http://www.scopus.com/inward/record.url?scp=85200216741&partnerID=8YFLogxK
U2 - 10.3389/fmicb.2024.1413250
DO - 10.3389/fmicb.2024.1413250
M3 - Review article
AN - SCOPUS:85200216741
SN - 1664-302X
VL - 15
JO - Frontiers in Microbiology
JF - Frontiers in Microbiology
M1 - 1413250
ER -